Management of heart failure with reduced ejection fraction after ESC 2016 heart failure guidelines: the Linx Registry

de Frutos, Fernando; Mirabet, Sonia; Ortega-Paz, Luis; Buera, Irene; Darnés, Sara; Farré López, Núria; Pérez, Bernardo; Adeliño, Raquel; Bascompte, Ramón; Pérez-Rodón, Jordi; Aparicio, Xavier; Sutil-Vega, Mario; Soto, Adriana; Faraudo, Mercedes; Cainzos-Achirica, Miguel; Manito Lorite, Nicolás

doi:http://dx.doi.org/10.1002/ehf2.12567

Management of heart failure with reduced ejection fraction after ESC 2016 heart failure guidelines: the Linx Registry

Citation

de Frutos F, Mirabet S, Ortega-Paz L, Buera I, Darnés S, Farré N, et al. Management of heart failure with reduced ejection fraction after ESC 2016 heart failure guidelines: the Linx Registry. ESC Heart Fail. 2020 Feb; 7(1):25-35. DOI: 10.1002/ehf2.12567

Abstract

Aims: In May 2016, a new version of the European Society of Cardiology (ESC) Guidelines for the management of heart failure (HF) was released. The aim of this study was to describe the management of HF with reduced ejection fraction after the publication of ESC Guidelines. Methods and results: The Linx registry is a multicentre, observational, cross-sectional study from 14 Catalan hospitals that enrolled 1056 patients with HF and reduced left ventricular ejection fraction (≤40%) from 1 February to 30 April 2017 in outpatient cardiology clinics. Results were compared between hospitals according to their level of complexity in our own registry and compared with previously published registries similar to ours. Sacubitril/valsartan was prescribed to 23.9% of patients in our population, as a consequence, use of angiotensin-converting enzyme inhibitor and angiotensin receptor blockers in monotherapy decreased to 48.1% and 16.9%, respectively, and prescription of beta-blockers (91.8%), mineralocorticoid receptor antagonists (72.7%), and ivabradine (21.4%) remained similar to previous registries. Target doses of beta-blockers (25.4%), angiotensin-converting enzyme inhibitors (24.9%), angiotensin receptor blockers (7.7%), sacubitril/valsartan (8.1%), and mineralocorticoid receptor antagonists (19.7%) were accomplished in a low proportion of patients. Our results also suggest that prescription and up-titration of class I HF drugs were greater in hospitals with higher level of complexity. Conclusions: The Linx registry shows an appropriate adherence to pharmacological recommendations from ESC HF Guidelines despite a low proportion of patients reached target doses. Almost one-quarter of patients were under treatment with sacubitril/valsartan a few months after ESC HF Guidelines recommendations.